Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with Dyskinesia

Journal of Parkinson's Disease

Volumn 1, Issue 4, 2011, Pages 347-357

  Lindgren, H S ^a   Rylander, D ^a   Iderberg, H ^a   Andersson, M ^b   O'Sullivan, S S ^c   Williams, D R ^c   Lees, A J ^c   Cenci, M A ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

dopaminergic therapies; immediate early genes; medium spiny neurons; Motor complications; neurodegeneration; striatonigral; striatopallidal

Indexed keywords

LEVODOPA; TRANSCRIPTION FACTOR DELTA FOSB;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; BRAIN REGION; CADAVER; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MOLECULAR DYNAMICS; MOTOR CORTEX; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUTAMEN; TREATMENT DURATION; UPREGULATION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; BASAL GANGLIA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; NEURONS; PARKINSON DISEASE; POSTMORTEM CHANGES; PROTO-ONCOGENE PROTEINS C-FOS; PUTAMEN; UP-REGULATION;

EID: 84863229146     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11068     Document Type: Article

References (56)

1. Nutt JG (1990) Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology, 40(2), 340-345.
2. Schrag A, & Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain, 123(Pt 11), 2297-2305.
3. Fabbrini G, et al. (2007) Levodopa-induced dyskinesias. Mov Disord, 22(10), 1379-1389; quiz 1523.
4. OlanowCW, et al. (2004) Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord, 19(9), 997-1005.
5. Grandas F, Galiano ML, & Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol, 246(12), 1127-1133.
6. Andersson M, Hilbertson A,&CenciMA(1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis, 6(6), 461-474.
7. Calon F, et al. (2000) Molecular basis of levodopa-induced dyskinesias. Ann Neurol, 47(4) (Suppl 1), S70-S78.
8. Cenci MA, Lee CS, & Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci, 10(8), 2694-2706.
9. Tel BC, et al. (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA: Ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience, 115(4), 1047-1058.
10. Henry B, Crossman AR, & Brotchie JM (1998) Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol, 151(2), 334-342.
11. Andersson M, Konradi C, & Cenci MA (2001) cAMP response element-binding protein is required for dopaminedependent gene expression in the intact but not the dopaminedenervated striatum. J Neurosci, 21(24), 9930-9943.
12. Konradi C,Westin JE, Carta M, Eaton ME,Kuter K, Dekundy A, Lundblad M, & Cenci MA (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis, 17(2), 219-236.
13. Crocker SJ, et al. (1998) D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression. Brain Res Mol Brain Res, 53(1-2), 69-77.
14. Doucet JP, et al. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci, 8(2), 365-381.
15. Hiroi N, et al. (1997) FosB mutant mice: Loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci U S A, 94(19), 10397-10402.
16. Hope BT, et al. (1994) Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron, 13(5), 1235-1244.
17. Maries E, et al. (2006) Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis, 21(1), 165-180.
18. Cao X, et al. (2010) Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci, 30(21), 7335-7343.
19. Fasano S, et al. (2010) Inhibition of Ras-guanine nucleotidereleasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A, 107(50), 21824-21829.
20. Berton O, et al. (2009) Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry, 66(6), 554-561.
21. Tekumalla PK, et al. (2001) Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry, 50(10), 813-816.
22. Cenci MA, et al. (1999) Changes in the regional and compartmental distribution of FosB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience, 94(2), 515-527.
23. Westin JE, et al. (2001) Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci, 14(7), 1171-1176.
24. Kingsbury A, Bray E, & Foster O (1996) A simplified and rapid procedure for in situ hybridization on human. J Neurosci Methods, 69(213-227), T-ppublish.
25. Mai JG, Paxinos G,&Voss T (2007) Atlas of the human brain, Elsevier Academic Press.
26. Eve DJ, et al. (1998) Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res, 63(1), 62-71.
27. Winkler C, Kirik D, Bjorklund A, & Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis, 10(2), 165-186.
28. Grande C, et al. (2004) Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry, 55(5), 457-463.
29. Ogita K, et al. (2002) Localization of activator protein-1 complex with DNA binding activity in mitochondria of murine brain after in vivo treatment with kainate. J Neurosci, 22(7), 2561-2570.
30. Pavon N, et al. (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry, 59(1), 64-74.
31. Zachariou V, et al. (2006) An essential role for DeltaFosB in the nucleus accumbens in morphine action. Nat Neurosci, 9(2), 205-211.
32. Huot P, et al. (2012) 5-HT(2A) receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiol Aging, 33(1), 207.e9-207.e19.
33. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA. (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L- alanine-induced dyskinesia. J Neurosci, 26(37), 9448-9461.
34. Lundblad M, et al. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinsonś disease. Eur J Neurosci, 15, 120-132.
35. Parent A, & Hazrati LN (1995) Functional anatomy of the basal ganglia I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev, 20(1), 91-127.
36. Chen J, et al. (1997) Chronic Fos-related antigens: Stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci, 17(13), 4933-4941.
37. Sgambato-Faure V, et al. (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol, 64(11), 936-947.
38. Saka E, et al. (1999) Compartmental changes in expression of c-Fos and FosB proteins in intact and dopamine-depleted striatum after chronic apomorphine treatment. Brain Res, 825(1-2), 104-114.
39. Lundblad M, Vaudano E, & Cenci MA (2003) Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem, 84(6), 1398-1410.
40. Reiner A, Medina L, & Veenman CL (1998) Structural and functional evolution of the basal ganglia in vertebrates. Brain Res Brain Res Rev, 28(3), 235-285.
41. Ohlin KE, et al. (2011) Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: Implications for the development of dyskinesia. Brain, 134(Pt 8), 2339-2357.
42. Valastro B, et al. (2007) Expression pattern of JunD after acute or chronic L-DOPA treatment: Comparison with deltaFosB. Neuroscience, 144(1), 198-207.
43. Miano JM, et al. (1993) Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol, 142(3), 715-724.
44. Rothman A, et al. (1994) Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells. J Biol Chem, 269(9), 6399-6404.
45. Holmes DI, & Zachary I (2004) Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett, 557(1-3), 93-98.
46. Kovary K, & Bravo R (1991) Expression of different Jun and Fos proteins during the G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations. Mol Cell Biol, 11(5), 2451-2459.
47. Dickinson JA, et al. (1995) Membrane immunoglobulin receptor cross-linking induces fosB mRNA expression in matureBlymphocytes: Assembly of distinct FosB-containing nucleoprotein complexes during B cell stimulation. Cell Immunol, 165(1), 92-100.
48. Cenci MA, et al. (2002) Striatal expression of FosB-related transcription factors in human Parkinson's disease: Relation to L-DOPA-induced dyskinesia. Mov Disord, 17(Suppl 5), S98.
49. McClung CA, et al. (2004) DeltaFosB: A molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res, 132(2), 146-154.
50. Gerfen CR (1992) The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci, 15, 285-320.
51. Papa SM, et al. (1999) Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol, 46(5), 732-738.
52. Bezard E, Brotchie JM,&Gross CE (2001) Pathophysiologyz of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci, 2(8), 577-588.
53. CenciMA(2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci, 30(5), 236-243.
54. Cenci MA,&LindgrenHS(2007) Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol, 17(6), 665-671.
55. Cyr M, et al. (2003) Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A, 100(19), 11035-11040.
56. NaydenovAV, et al. (2010) Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia. Acta Neuropathol, 120(5), 623-631.